D. Bayik

Tumor cell-derived spermidine promotes a pro-tumorigenic immune microenvironment in glioblastoma via CD8+ T cell inhibition

This study shows that spermidine, a metabolite from glioblastoma cells, suppresses CD8+ T cell function, promoting tumor growth and poor patient outcomes.

Sex-specific T cell exhaustion drives differential immune responses in glioblastoma

This study shows male T cells are more exhausted in glioblastoma, leading to worse outcomes and better response to anti-PD1 treatment compared to females.

SerpinB3 drives cancer stem cell survival in glioblastoma

This study identifies SerpinB3 as a key driver of glioblastoma cancer stem cell survival and shows that targeting it enhances radiation therapy efficacy in pre-clinical models.

Distinct cell adhesion signature defines glioblastoma myeloid-derived suppressor cell subsets

The paper identifies distinct cell adhesion signatures in glioblastoma myeloid-derived suppressor cell subsets, showing that monocytic MDSCs drive tumor growth through enhanced integrin β1 expression.

Horizontal mitochondrial transfer from the microenvironment increases glioblastoma tumorigenicity

The paper identifies horizontal mitochondrial transfer from astrocytes to glioblastoma cells as a mechanism that enhances tumorigenicity by improving mitochondrial function and metabolic capacity.

Preclinical modeling of surgery and steroid therapy for glioblastoma reveals changes in immunophenotype that are associated with tumor growth and outcome

The paper develops a mouse model to study how surgery and steroids affect immune responses in glioblastoma, finding systemic lymphocyte reduction and correlations with tumor growth and patient outcomes.

Disruption of the gut microbiota attenuates epithelial ovarian cancer sensitivity to cisplatin therapy

This study shows that antibiotic treatment disrupts the gut microbiome, leading to increased resistance to cisplatin in ovarian cancer models.

Myeloid-derived suppressor cell subsets drive glioblastoma growth in a sex-specific manner

This study identifies sex-specific roles of MDSC subsets in glioblastoma, showing mMDSCs drive growth in males and gMDSCs in females, with potential therapeutic targets.

Glioblastoma myeloid-derived suppressor cell subsets express differential macrophage migration inhibitory factor receptor profiles that can be targeted to reduce immune suppression

This study identifies differential MIF receptor expression in GBM MDSC subsets and shows targeting M-MDSCs with ibudilast reduces immune suppression.

Cholangiocarcinoma presents a distinct myeloid-derived suppressor cell signature compared to other hepatobiliary cancers

The paper identifies a distinct myeloid-derived suppressor cell (MDSC) signature in cholangiocarcinoma (CCA) compared to other hepatobiliary cancers, linking MDSC levels to disease outcomes and potential therapeutic targets.

JAM-A functions as a female microglial tumor suppressor in glioblastoma

This study shows that JAM-A deficiency in female mice increases microglia activation and GBM growth, revealing a sex-specific role for JAM-A in the tumor microenvironment.

MBOAT7-Driven Phosphatidylinositol Remodeling Promotes the Progression of Clear Cell Renal Cell Carcinoma.

This study identifies MBOAT7-driven phosphatidylinositol remodeling as a driver of clear cell renal cell carcinoma progression and highlights MBOAT7 as a potential therapeutic target.

Global immune fingerprinting in glioblastoma reveals immune-suppression signatures associated with prognosis

The paper identifies immune-suppression signatures in glioblastoma (GBM) patients, showing elevated myeloid-derived suppressor cells (MDSCs) linked to poor prognosis and reduced survival.